20231
ORBO™ 24 2-HMP en Amberlite™ XAD®-2 (20/40), 150/75 mg
W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 25 ea
Sinónimos:
ORBO™ 2-HMP on Supelpak™ 20N Tube
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
UNSPSC Code:
47131900
NACRES:
NB.21
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlematerial
W,W,W separators
Quality Level
agency
EPA TO-15, OSHA 52,61
product line
Amberlite™, ORBO™
composition
Bed A, 150 mg , Bed B, 75 mg
packaging
pkg of 25 ea
manufacturer/tradename
ORBO™ 24
technique(s)
active air sampling: suitable
O.D. × L
6 mm × 105 mm
matrix
XAD-2 2-(Hydroxymethyl)piperidine (2-HMP) on XAD-2
particle size
20-40 mesh
application(s)
air monitoring
environmental
industrial hygiene
storage temp.
2-8°C
Legal Information
Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
Supelpak is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Skin Corr. 1B
Clase de almacenamiento
8A - Combustible corrosive hazardous materials
wgk
WGK 3
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
F J Egea González et al.
Journal of AOAC International, 80(5), 1091-1097 (1997-11-05)
A method to sample and analyze chlorothalonil and dichlofluanid in greenhouse air was evaluated. Analysis was performed by gas chromatography with electron capture detection and gas chromatography-mass spectrometry. Solid sorbents such as Chromosorb 102, Porapak R, Supelpak-2, Amberlite XAD-2, Amberlite
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.